TEMPE, Ariz. and PRAGUE, July 10, 2025 /PRNewswire/ -- Gen Digital Inc. (NASDAQ: GEN) today announced that its fiscal 2026 first quarter financial results will be released Thursday, August 7, 2025, after market close. Following the press release, Gen management will host a conference call and webcast at 2 p.m. PT / 5 p.m. ET.Fiscal 2026 Q1 Earnings CallAugust 7, 20252 p.m. PT / 5 p.m. ETConference call dial-in and live webcast link available on Investor.GenDigital.com About GenGen (NASDAQ: GEN) is a global ...

Families urged to prioritize Cyber Safety education as over half of older loved ones have fallen victim to cybercrimeTEMPE, Ariz. and PRAGUE, July 8, 2025 /PRNewswire/ -- As people try to keep up with rapidly evolving online safety threats and scams, their parents and grandparents may need their help. According to Avast, a consumer Cyber Safety brand of Gen (NASDAQ: GEN), 59% of people's older loved ones have fallen victim to cybercrime. Avast has found over 80% of cybercrime is originating from scams and s ...

RT ckim001🥑 (@hmmm0100)Jewish June. July? DON'T KNOW.First vid I made last week mixing @HoloworldAI AvaStudio ($ava) + some other tools (explains my shitty subtitles etc. kek).Special mentions @DegenPing @MustStopMurad @theunipcs @DipWheeler @ChillHouseSOL @BigDickBull69 @trading_axe @AVA_holo https://t.co/ZovUr4HURa ...

Avast debuts Scam Guardian and Scam Guardian Pro as data breaches and scams soar TEMPE, Ariz. and PRAGUE, June 25, 2025 /PRNewswire/ -- Driven by a commitment to make cutting-edge scam protection available to everyone, Avast, a leader in digital security and privacy and part of Gen (NASDAQ: GEN), has unveiled Scam Guardian, a new AI-powered offering integrated into its award- winning1 Avast Free Antivirus. Avast debuts Scam Guardian and Scam Guardian Pro Avast debuts Scam Guardian and Scam Guardian Pro Abou ...

Core Viewpoint - Summit Therapeutics' stock experienced a significant decline of over 30% due to disappointing results from the Harmoni trial of ivonescimab, a bispecific antibody aimed at treating lung cancer [1][2]. Group 1: Clinical Trial Results - The Harmoni trial aimed to evaluate ivonescimab in second-line lung cancer patients, showing a 48% reduction in disease progression risk but failing to demonstrate a statistically significant overall survival benefit [6]. - The treatment reduced the risk of death by 21%, but the results were just outside the 95% confidence interval with a p-value of 0.057, indicating a lack of convincing evidence for overall survival [6][7]. - The FDA is unlikely to approve ivonescimab in the U.S. based on these trial results, as a statistically significant overall survival benefit is required for approval [7]. Group 2: Market Context and Comparisons - Keytruda, a leading treatment for lung cancer, generated $29.5 billion in sales last year, setting a high benchmark for any competing therapies like ivonescimab [9]. - Despite the lack of overall survival data, ivonescimab's ability to shrink tumors suggests potential for future success in different patient populations [9][11]. - The stock of Summit Therapeutics finished May with a market cap exceeding $13.5 billion, despite having no sales and only one candidate in its pipeline [12]. Group 3: Investment Considerations - The lack of convincing overall survival data for ivonescimab diminishes the likelihood of it achieving blockbuster sales, even if it eventually receives FDA approval [11][13]. - Investors may face challenges ahead, as expectations remain high despite the uncertain path for ivonescimab [11].

Core Insights - The Q1/2025 Gen Threat Report reveals significant increases in cyber threats, including a 186% rise in breached personal information and a 466% increase in phishing reports [2][4][5] - The report highlights the evolution of online threats, with attackers utilizing AI and personalized tactics to enhance deception [3][7] - Gen has successfully protected over 4 million users from Scam-Yourself Attacks, which involve individuals being manipulated into compromising their own devices [7][8] Data Breaches - There was a 36% increase in the number of data breaches faced by companies compared to the previous quarter, with individual breached records rising by over 186% [4] - Attackers are employing advanced infostealers, making data compromise faster and harder to detect [4] Phishing Scams - Phishing reports surged by 466%, now accounting for nearly 32% of all scam submissions to the Norton Genie scam detector [5] - Phishing is identified as the fastest-growing threat, with generic scams making up 51% of reports [5] - Attackers are using dynamic DNS services and subdomain providers to create deceptive login pages, making phishing attempts harder to detect [6] Scam-Yourself Attacks - Gen protected over 4 million users from Scam-Yourself Attacks, where individuals are tricked into infecting their own devices [7] - Attackers are utilizing AI-generated personas and deepfake influencers to deliver malicious campaigns [7] - Fake browser update scams have increased to over 17 times the previous quarter's levels, tricking users into installing malware [8] Financial Threats - Mobile financial threats are on the rise, with malware exploiting accessibility features to steal sensitive data [10] - Digital currencies are increasingly targeted, with one campaign linked to the US presidential inauguration resulting in nearly $4 million stolen through over 2,000 transactions [11] Company Overview - Gen is a global leader in Cyber Safety, providing solutions through trusted brands like Norton, Avast, and LifeLock [1][13] - The company aims to empower individuals to live their digital lives safely and confidently, serving nearly 500 million users in over 150 countries [13]

Bioatla (BCAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Bruce Mackle - Managing DirectorJay Short - Co-Founder, CEO & ChairmanRichard Waldron - Chief Financial OfficerEric Sievers - Chief Medical OfficerReni Benjamin - Managing DirectorYu He (Arthur) - Equity Research Vice President Conference Call Participants Jeet Mukherjee - Vice President & Biotechnology Analyst Operator Good day, everyone, and welcome to today's BioAtlas First Quarter twenty twenty five Earnings Call. At this ...

Bioatla (BCAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to today's BioAtlas First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. I will be standing by should you need any assistance. And it is now my pleasure to turn the conference over to Bruce Mackle with LifeSci Advisors. Please go ahead. Speaker1 Thank you, opera ...

Core Insights - Corcept Therapeutics reported first-quarter 2025 earnings of 17 cents per share, matching the Zacks Consensus Estimate, but down from 25 cents per share in the same quarter last year [1] - Revenues for the first quarter increased by 7.1% year over year to $157.2 million, but fell short of the Zacks Consensus Estimate of $178 million, primarily driven by sales of the Cushing's syndrome drug, Korlym [2][5] - Year-to-date, Corcept's shares have increased by 46.8%, contrasting with a 0.4% decline in the industry [4] Financial Performance - Korlym sales were impacted by the inability of a specialty pharmacy vendor to meet the surge in demand, leading to lower-than-expected sales and a 7.5% drop in shares during after-hours trading following the earnings announcement [5] - Research and development expenses rose by 3.8% year over year to $60.7 million, while selling, general, and administrative expenses surged by approximately 61.1% to $90.7 million, resulting in total operating expenses increasing by 31.1% to $153.8 million [6] - As of March 31, 2025, cash and investments totaled $570.8 million, down from $603.2 million as of December 31, 2024 [6] 2025 Guidance - Corcept reiterated its total revenue guidance for 2025, expecting revenues in the range of $900-$950 million, with the Zacks Consensus Estimate at $905.7 million [7] Pipeline Developments - Corcept is advancing its lead candidate, relacorilant, for Cushing's syndrome, with a new drug application submitted to the FDA in December 2024 based on positive data from the GRACE study and other trials [8] - The FDA accepted the NDA in March 2025, with a target action date of December 30, 2025 [9] - Corcept is also exploring relacorilant in combination studies for various cancer indications, with the phase III ROSELLA study meeting its primary endpoint for patients with platinum-resistant ovarian cancer [9] Additional Studies - Corcept initiated the phase II BELLA study to evaluate relacorilant in combination with nab-paclitaxel and Avastin for treating platinum-resistant ovarian cancer [10] - The company is also assessing relacorilant plus Xtandi in early-stage prostate cancer patients in collaboration with the University of Chicago [11] - Data from the phase II DAZALS study for dazucorilant in ALS did not meet its primary endpoint, but exploratory analysis showed improved overall survival for treated patients [12][13] Market Position - Corcept currently holds a Zacks Rank 3 (Hold), with better-ranked biotech stocks including ADMA Biologics and Immunocore Holdings, both carrying a Zacks Rank 2 (Buy) [14]

Bioatla (BCAB) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Bruce Mackle - Managing DirectorJay Short - Co-Founder, CEO & ChairmanRichard Waldron - Chief Financial OfficerEric Sievers - Chief Medical OfficerSheri Lydick - Chief Commercial OfficerTony Butler - Senior Managing Director Conference Call Participants Jeet Mukherjee - AnalystNone - AnalystArthur He - Analyst Operator is now my pleasure to turn the conference over to Mr. Bruce Mackle of LifeSci Advisors. Please go ahead, s ...